EP3065549A4 - Methods for inhibiting tie2 kinase useful in the treatment of cancer - Google Patents

Methods for inhibiting tie2 kinase useful in the treatment of cancer Download PDF

Info

Publication number
EP3065549A4
EP3065549A4 EP13896951.4A EP13896951A EP3065549A4 EP 3065549 A4 EP3065549 A4 EP 3065549A4 EP 13896951 A EP13896951 A EP 13896951A EP 3065549 A4 EP3065549 A4 EP 3065549A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
methods
tie2 kinase
kinase useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP13896951.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3065549A1 (en
Inventor
Daniel L. Flynn
Michael D. Kaufman
Bryan Smith
Marc S. RUDOLTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of EP3065549A1 publication Critical patent/EP3065549A1/en
Publication of EP3065549A4 publication Critical patent/EP3065549A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13896951.4A 2013-11-07 2013-11-07 Methods for inhibiting tie2 kinase useful in the treatment of cancer Ceased EP3065549A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/069005 WO2015069266A1 (en) 2013-11-07 2013-11-07 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
EP3065549A1 EP3065549A1 (en) 2016-09-14
EP3065549A4 true EP3065549A4 (en) 2017-05-24

Family

ID=53041876

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13896951.4A Ceased EP3065549A4 (en) 2013-11-07 2013-11-07 Methods for inhibiting tie2 kinase useful in the treatment of cancer

Country Status (7)

Country Link
EP (1) EP3065549A4 (zh)
JP (1) JP6568093B2 (zh)
KR (2) KR20160070188A (zh)
CN (2) CN105873440B (zh)
AU (3) AU2013404949B2 (zh)
CA (1) CA2929715A1 (zh)
WO (1) WO2015069266A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
WO2016191401A1 (en) * 2015-05-27 2016-12-01 Albert Einstein College Of Medicine, Inc. Tmem active test and uses thereof in diagnosis, prognosis and treatment of tumors
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106822128A (zh) * 2017-02-24 2017-06-13 南华大学附属第医院 酪氨酸激酶抑制剂dcc‑2036的新应用
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
TW202122085A (zh) * 2019-08-12 2021-06-16 美商迪賽孚爾製藥公司 治療血管畸形之方法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130023587A1 (en) * 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
WO2011150198A1 (en) * 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2012097021A1 (en) * 2011-01-11 2012-07-19 Glaxosmithkline Llc Combination
MX359664B (es) * 2011-07-29 2018-10-05 Univ Colorado Regents Tratamiento de cáncer de mama.
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRYAN D SMITH ET AL: "Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model", February 2013 (2013-02-01), XP002769061, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/3_Supplement/B78> [retrieved on 20170410] *
JAVIER CORTES ET AL: "Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study", THE LANCET, vol. 377, no. 9769, 1 March 2011 (2011-03-01), pages 914 - 923, XP055030961, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(11)60070-6 *
See also references of WO2015069266A1 *

Also Published As

Publication number Publication date
AU2019200261A1 (en) 2019-01-31
KR20210063475A (ko) 2021-06-01
AU2013404949B2 (en) 2018-10-18
KR20160070188A (ko) 2016-06-17
WO2015069266A1 (en) 2015-05-14
CN105873440B (zh) 2018-06-01
JP6568093B2 (ja) 2019-08-28
CN105873440A (zh) 2016-08-17
JP2017500371A (ja) 2017-01-05
CN108464981A (zh) 2018-08-31
AU2013404949A1 (en) 2016-05-26
CA2929715A1 (en) 2015-05-14
EP3065549A1 (en) 2016-09-14
AU2021200113A1 (en) 2021-03-04
CN108464981B (zh) 2022-06-24

Similar Documents

Publication Publication Date Title
EP3065549A4 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
IL273090B (en) Methods and preparations for the treatment of cancer
EP3027192A4 (en) Methods for the treatment of solid tumors
HK1202247A1 (zh) 激酶抑制劑治療癌症
HK1201750A1 (zh) 使用 激酶抑制劑的癌症治療
HK1201753A1 (zh) 使用 激酶抑制劑的癌症治療
EP3004396A4 (en) Methods and compositions for the treatment of cancer
EP3008212A4 (en) Methods of treatment of cancer
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
EP3252171B8 (en) Methods of treating cancer
HK1223547A1 (zh) 癌症治療方法
HK1223832A1 (zh) 用於癌症治療的激酶抑制劑
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/357 20060101ALI20170411BHEP

Ipc: A61P 35/00 20060101ALI20170411BHEP

Ipc: A61K 31/337 20060101ALI20170411BHEP

Ipc: A61K 31/4709 20060101AFI20170411BHEP

Ipc: A61K 45/06 20060101ALI20170411BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170424

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228670

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DECIPHERA PHARMACEUTICALS, LLC

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20221120